Objective-To review the importance of heart rate variability analysis in left ventricular dysfinction and heart failure and to assess the effects of drug treatment. In patients with left ventricular dysfunction or heart fiilure, a low heart rate variability is a strong predictor of a low probability of survival. Because drug treatment in these patients has rapidly changed over the past two decades, the effect of these drugs on heart rate variability needs special attention. Design-A study of published reports to give an overview of heart rate variability in patients with left ventricular dysfunction or heart failure and how it is affected by drug treatment. Results-Analysis of heart rate variability provides an easily obtained early marker for progression of disease. It seems to be more closely related to the degree of neurohumoral activation than to haemodynamic variables. Cardiovascular drugs may either stimulate or inhibit the degree of neurohumoral activation, and the effects of pharmacological intervention can be closely monitored with this method. Conclusions-The analysis of heart rate variability, including spectral analysis, is a novel non-invasive way to obtain potentially useful clinical information in patients with reduced left ventricular function. The effects of drug treatment on heart rate variability are in general consistent with their long-term effects in left ventricular dysfunction and heart failure. (Br HeartJ 1994;72:509-513) Heart rate (HR) 
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To provide information about neurohumoral maladaptation in heart failure it was suggested that impairment of HR variability should be examined. 26 We recently studied the relation between neurohumoral activation and HR variability in a large group of patients with chronic heart failure.27 A negative correlation was found between plasma noradrenaline concentrations and relatively slow fluctuations in HR variability (r = -030 to -O0 34, P < 0-01; fig 2) . Furthermore, a significant positive correlation was found between ejection fraction and more rapidly fluctuating HR variability parameters (r = 0-30; P < 0-05).27 Also, we recently dis-SD (ms) rMSSD (ms) pNN50 () covered that short-term improvement of haemodynamics improved HR variability in patients with severe chronic heart failure,28 ;ubsequent LV dilatation.21 Before which underlines the relation between from hospital, at a time when LV haemodynamic and autonomic function. vas still normal, patients with a low Only two studies have so far investigated bility index had a significantly higher the predictive value of HR variability in ubsequent dilatation compared with chronic heart failure.29 30 Binder et al showed ith a high index.21 Furthermore, that HR variability was the most powerful vho developed an increase in LV end predictor of an increased risk of cardiac death 7olume after three months showed in patients on a waiting list for heart transny improvement in HR variability, plantation,29 and Woo et al found that a in those without LV dilatation HR reduced HR variability indicated an increased had clearly improved after three likelihood of sudden death.30 months follow up (fig 1) . 22 Among the first to study HR va chronic heart failure were Saul e showed that patients with advancec ure had a considerably reduced H ity. Casolo and coworkers wer confirm these findings. 24 plasma noradrenaline, and to a lesser extent, plasma aldosterone and renin.34 55 In a recent placebo controlled study in patients with chronic heart failure, ibopamine partly prevented the deterioration of HR variability found in the placebo group. This paralleled the mild neurohumoral effects of ibopamine.53
By contrast with drugs that inhibit neurohumoral activation in heart failure, as discussed earlier, other drugs do not affect or even enhance neurohumoral activation, including calcium channel blockers, diuretics, positive inotropic agents and antiarrhythmic drugs.
CALCIUM CHANNEL BLOCKERS
The use of calcium channel blockers in LV dysfunction and chronic heart failure is still controversial. Apart from small reports in patients with primarily diastolic dysfunction,56 so far there are no long-term studies that show positive results. Negative findings have been primarily attributed to the negative inotropic effects of calcium channel blockers and their ability to increase or at least not inhibit neurohumoral activation.57 Cook et al could not show any effect of diltiazem on HR variability in normal subjects.58 After myocardial infarction, however, diltiazem was found to reduce low frequency power.59 To our knowledge, there are no long-term data on the effects of calcium channel blockers on HR variability in patients with heart failure.
DIURETICS
Diuretics are effective in the treatment of acute heart failure, by reducing volume overload. Paradoxically in this condition, diuretics may be able to inhibit neurohumoral activation.60 In chronic heart failure, however, neurohumoral activity is less pronounced, and diuretics may in fact further stimulate neurohumoral activity, particularly the reninangiotensin system. 6 
